Mercury ban will hit exporters to Europe
This article was originally published in Clinica
Executive Summary
The European Commission's proposal to ban mercury in medical instruments sold to the general public would only impact a small number of small to medium-sized enterprises (SMEs) in the EU. But companies exporting to the EU from China, India and Japan are likely to be badly hit. That is the Commission's view, as expressed in its Impact Assessment of the proposal that it has just published (see Clinica No 1194, p 4).
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.